Fibrosarcoma is a rare, aggressive cancer originating in fibrous connective tissues, affecting both adults and children. Recent research has shed light on the genetic and molecular drivers of this malignancy, revealing critical mutations in the fibroblast growth factor receptor (FGFR) and other pathways that promote tumor growth. Cutting-edge treatments, including targeted therapies and immunotherapies, are being developed to improve patient outcomes. Enhanced diagnostic techniques, such as advanced imaging and precise biopsy methods, facilitate early detection, which is vital for effective treatment. Current clinical trials are focused on optimizing these innovative therapies, offering new hope for patients with fibrosarcoma.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China